317 patients were included in this double blind randomized trial for 12 weeks with either placebo or flexible dosed dasotraline at 4 mg/day, 6 mg/day, and 8 mg/day. Dasotraline is a dual acting norepinephrine and dopamine reuptake inhibitor.
Results showed the mean drop of binge eating days per week was greater with dasotraline at -3.74 vs -2.75 for placebo. Dasotraline performed better on mean endpoint changes on the Yale Brown Obsessive Compulsive Scale Modified for Binge Eating total scores -17.05 vs -9.88, compulsion subscale score -8.69 vs -5.35, and obsession subscale score -8.32 vs -4.58. The mean endpoint change was greater with dasotraline on the Eating Disorder Examination Brief Version on the global score -0.93 vs -0.43, and weight concern -1.03 vs -0.44.
Dasotraline has also been shown to improve ADHD symptoms in children in a phase 3 trail for up to 24 hours, in a 2 weeks randomized double blind study involving 112 children.
